These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation. Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764 [TBL] [Abstract][Full Text] [Related]
4. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Vaughn CP; Zobell SD; Furtado LV; Baker CL; Samowitz WS Genes Chromosomes Cancer; 2011 May; 50(5):307-12. PubMed ID: 21305640 [TBL] [Abstract][Full Text] [Related]
5. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer. Netzel BC; Grebe SK Clin Chim Acta; 2013 Oct; 425():1-2. PubMed ID: 23832066 [TBL] [Abstract][Full Text] [Related]
6. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Guerrero S; Casanova I; Farré L; Mazo A; Capellà G; Mangues R Cancer Res; 2000 Dec; 60(23):6750-6. PubMed ID: 11118062 [TBL] [Abstract][Full Text] [Related]
7. Human pancreatic duct epithelial cell model for KRAS transformation. Radulovich N; Qian JY; Tsao MS Methods Enzymol; 2008; 439():1-13. PubMed ID: 18374152 [TBL] [Abstract][Full Text] [Related]
8. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer. Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002 [TBL] [Abstract][Full Text] [Related]
9. Glycine-cysteine substitution at codon 13 of the N-ras proto-oncogene in a human T cell non-Hodgkin's lymphoma. Wodnar-Filipowicz A; Senn HP; Jiricny J; Signer E; Moroni C Oncogene; 1987; 1(4):457-61. PubMed ID: 3330790 [TBL] [Abstract][Full Text] [Related]
10. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling. Moon BS; Jeong WJ; Park J; Kim TI; Min do S; Choi KY J Natl Cancer Inst; 2014 Feb; 106(2):djt373. PubMed ID: 24491301 [TBL] [Abstract][Full Text] [Related]
11. Mutation bias within oncogene families is related to proliferation-specific codon usage. Benisty H; Weber M; Hernandez-Alias X; Schaefer MH; Serrano L Proc Natl Acad Sci U S A; 2020 Dec; 117(48):30848-30856. PubMed ID: 33199641 [TBL] [Abstract][Full Text] [Related]
12. H-ras and raf-1 cooperate in transformation of NIH3T3 fibroblasts. Cuadrado A; Bruder JT; Heidaran MA; App H; Rapp UR; Aaronson SA Oncogene; 1993 Sep; 8(9):2443-8. PubMed ID: 8361757 [TBL] [Abstract][Full Text] [Related]
13. ¹H, ¹³C and ¹⁵N resonance assignment for the human K-Ras at physiological pH. Vo U; Embrey KJ; Breeze AL; Golovanov AP Biomol NMR Assign; 2013 Oct; 7(2):215-9. PubMed ID: 22886485 [TBL] [Abstract][Full Text] [Related]
14. Oncogenic KRAS promotes malignant brain tumors in zebrafish. Ju B; Chen W; Orr BA; Spitsbergen JM; Jia S; Eden CJ; Henson HE; Taylor MR Mol Cancer; 2015 Feb; 14(1):18. PubMed ID: 25644510 [TBL] [Abstract][Full Text] [Related]
16. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Modest DP; Stintzing S; Laubender RP; Neumann J; Jung A; Giessen C; Haas M; Aubele P; Schulz C; Boeck S; Stemmler HJ; Kirchner T; Heinemann V Anticancer Drugs; 2011 Oct; 22(9):913-8. PubMed ID: 21795973 [TBL] [Abstract][Full Text] [Related]
17. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Capella G; Cronauer-Mitra S; Pienado MA; Perucho M Environ Health Perspect; 1991 Jun; 93():125-31. PubMed ID: 1685441 [TBL] [Abstract][Full Text] [Related]
18. MicroRNA-mediated regulation of KRAS in cancer. Kim M; Slack FJ J Hematol Oncol; 2014 Nov; 7():84. PubMed ID: 25433809 [TBL] [Abstract][Full Text] [Related]